Adecuación de la seguridad del metamizol y agranulocitosis

OBJECTIVE: To analyze whether the drug safety update issued by the Spanish Agency of Medicines and Healthcare Products (AEMPS), dated October 30, 2018, on agranulocytosis and metamizole contains accurate and necessary information to protect patients from the presentation of this adverse reaction (AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia del Campo, Cristina, Murcia Soler, Miguel, Martinez-Mir, Inocencia, Palop Larrea, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047160/
https://www.ncbi.nlm.nih.gov/pubmed/33823317
http://dx.doi.org/10.1016/j.aprim.2021.102047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047160/
https://www.ncbi.nlm.nih.gov/pubmed/33823317
http://dx.doi.org/10.1016/j.aprim.2021.102047

Ejemplares similares